Changes in the MRI Signal in Patients With Benign Tumors of the Brain and Meninges Treated With Proton Therapy: Impact of TEL and the Biological Dose Received (BRAIN TEL)

Centre Francois Baclesse

Status

Completed

Conditions

Benign Brain Tumors

Proton Therapy

Treatments

Device: MRI 3 tesla

Study type

Interventional

Funder types

Other

Identifiers

NCT04584086

2020-A02023-36

Details and patient eligibility

About

The main objective is to detect with TESLA multiparametric 3 MRI, the MRI secondary changes to protontherapy irradiation and to correlate them with TEL mapping, physical dose and biological dose. A model should thus be able to be proposed at the end of the study.

Enrollment

20 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically proven or highly probable grade I meningiomas, histologically proven grade II meningiomas.
Only meningiomas of the anterior and middle floors of the base of the skull are included.
Indication of proton therapy retained in RCP and / or proton therapy technical staff (Caen site)
Patient aged 18 or over
Patient affiliated to a social security scheme
Signature of informed consent before any specific procedure related to the study

Exclusion criteria

History of brain or face irradiation.
Implant or foreign body that can alter MRI imaging.
Contraindication to MRI (pace maker, claustrophobia ...) - Hypersensitivity to gadoteric acid, to meglumine or to any medicine containing gadolinium
Genetic radio sensitizing syndrome
Known neurological comorbidities (stroke, Parkinson's, etc.) that may impact MRI data.
Simultaneous participation in a therapeutic clinical trial
Patient unable to undergo the trial follow-up for geographic, social or psychopathological reasons
Pregnant or breastfeeding women
Persons deprived of their liberty (see article L 1121-6 CSP),
Adults who are the subject of a legal protection measure or unable to express their consent (see article L 1121-8)